Everest Medicines IPO: Valuation Insights
Ocumension Therapeutics (1477 HK) is a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing...
625 Views
Everest Medicines (云顶新耀) IPO: Overvalued for the Portfolio but Sentiment Is Strong
Everest Medicines is a China-based biotech company with late-stage drug candidates in-licensed from partner pharmaceutical companies and biotechs....
398 Views
ECM Weekly (27 September 2020) - Ant Group, Chindata, SCG Packaging, JHBP/Genor, Neuedu, UTI AMC
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Deal...
377 Views
Everest Medicines IPO Initiation: Potent Medicine
Everest Medicines Everest Medicines (EVEREST HK) is a biopharmaceutical company which targets four therapeutic areas - oncology, immunology,...
414 Views
Everest Medicines (云顶新耀) Pre-IPO: Thoughts on Valuation
Everest Medicines is a China-based biotech company with late-stage drug candidates in-licensed from partner pharmaceutical companies and...
596 Views